# The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

> **NCT07073053** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Taipei Veterans General Hospital, Taiwan** · enrollment: 60 (estimated)

## Conditions studied

- Glucagon-Like Peptide-1 Receptor Agonists
- Type 2 Diabetes
- Coronary Arterial Disease (CAD)

## Interventions

- **DRUG:** Semaglutide 1.0 mg
- **DRUG:** Semaglutide 0.5 mg

## Key facts

- **NCT ID:** NCT07073053
- **Lead sponsor:** Taipei Veterans General Hospital, Taiwan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07073053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07073053, "The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07073053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*